Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:23:32 08/07/2025 pm IST			5-day change	1st Jan Change
450.02 ^DKK	+2.00%		+2.29%	-28.16%

07:51pm	WeightWatchers names new medical chief, plans to offer menopause therapy and support	RE
07:20pm	Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	MT

Novo Nordisk's Wegovy's Increased Dose Helps Shed 21% Weight, Trial Results Show

Published on 22/06/2025 at 15:54

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Novo Nordisk A/S

WeightWatchers names new medical chief, plans to offer menopause therapy and support	07:51pm	RE
Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	07:20pm	MT
Novo Nordisk Seeks EU Approval for Higher Dose of Weight-loss Drug Wegovy	07:20pm	MT
Novo Nordisk Seeks Approval for Higher Dose of Wegovy	07:03pm	FW
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	07:03pm	RE
Novo Nordisk Seeks European Medicines Agency Approval for New, Higher Dose of Wegovy	06:57pm	MT
Novo Nordisk submits new Wegovy dose to the European Medicines Agency for approval	06:53pm	RE
Novo Nordisk submits application to EMA for approval of higher dose of Wegovy	06:50pm	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	04:15pm	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07/07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07/07	RE
The importance of being constantly changing…	07/07
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	07/07	RE
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	07/07	RE
European shares fall as banks, mining stocks losses weigh	04/07	RE
Jyske Bank Lowers Novo Nordisk Price Target to 700 Danish Kroner, Reiterates Buy - BN	04/07	FW
SAP Becomes Europe's Most Valuable Company as Nvidia Leads Globally	03/07	RE
NOVO NORDISK : UBS reiterates its Buy rating	03/07	ZD
Ascletis Pharma Begins Dosing Subjects in US Weight Management Drug Study; Shares Gain 3%	03/07	MT
How did Novo Nordisk lose the US market?	02/07
Novo Nordisk, WeightWatchers Expand Collaboration for Enhanced Access to Wegovy	02/07	MT
WW International, Inc. and Novo Nordisk Expand Collaboration to Improve Medication Access Through Trusted, Holistic Model of Care	02/07	CI
How Novo Nordisk misread the US market for its weight loss sensation	02/07	RE
How Novo Nordisk misread the US market for its weight loss sensation	02/07	RE
Sector Update: Health Care Stocks Advance Tuesday Afternoon	01/07	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

06/08 - Q2 2025 Earnings Release

More about the company